Menu
/REGISTER
Montecito
Nixon Peabody
Pac Premier
Loading...
You are here:  Home  >  'migraine'
Latest

Amgen, Novartis sue each other over migraine drug Aimovig

By   /  Friday, April 5th, 2019  /  Biotech, Central Coast Health Watch, East Ventura County, Latest news, Law  /  Comments Off on Amgen, Novartis sue each other over migraine drug Aimovig

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen gets FDA approval for migraine drug Aimovig

By   /  Thursday, May 17th, 2018  /  Central Coast Health Watch, East Ventura County, Latest news, Technology  /  Comments Off on Amgen gets FDA approval for migraine drug Aimovig

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen clinical trial shows promising results for migraine drug Aimovig

By   /  Tuesday, April 17th, 2018  /  Central Coast Health Watch, East Ventura County, Latest news, Technology  /  Comments Off on Amgen clinical trial shows promising results for migraine drug Aimovig

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen announces positive results for migraine drug

By   /  Thursday, September 29th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen announces positive results for migraine drug

Thousand Oaks-based biotech giant Amgen announced positive data from a phase 3 study of a new migraine drug co-developed with competitor Novartis. Amgen said in a news release that, after 12 weeks, Erenumab showed a significant reduction in monthly migraine days in patients with episodic migraines treated with Erenumab compared with a placebo. In the Read More →

Read More →